Hoth Therapeutics Expands Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics, Inc., a biopharmaceutical company listed on NASDAQ under the ticker HOTH, has received approval from the Institutional Review Boards (IRB) at Montefiore Medical Center and Dana-Farber Cancer Institute to initiate its First-in-Human (FIH) Phase 2a clinical trial. This trial will evaluate HT-001, a treatment aimed at mitigating skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

Robb Knie, Chief Executive Officer of Hoth Therapeutics, expressed satisfaction with the IRB approvals from these renowned medical institutions. He expressed optimism that the clinical trial would successfully demonstrate the efficacy of their leading therapeutic candidate, HT-001, potentially offering relief to cancer patients experiencing skin toxicities resulting from EGFRi treatments. Knie also mentioned that Hoth had concluded the previous quarter with over $9 million in cash and has no current intentions for additional capital raising in 2024.

The Phase 2a clinical trial is designed as a dose-ranging study to assess the efficacy, safety, and tolerability of topical HT-001 in treating skin toxicities linked to EGFRi. For more detailed information about the trial, interested parties can visit clinicaltrials.gov.

Hoth Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative treatments to improve patient quality of life. The company focuses on early-stage pharmaceutical research and development, advancing drugs from preliminary research to clinical testing. By adopting a patient-centric approach, Hoth collaborates with scientists, clinicians, and key opinion leaders to explore and investigate therapeutics with significant potential for breakthroughs, thereby expanding treatment options.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!